Iovance Biotherapeutics, Inc. (IOVA)

$8.43

-0.1

(-1.17%)

Market is closed - opens 7 PM, 14 Jun 2024

Insights on Iovance Biotherapeutics, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 81.8% return, outperforming this stock by 85.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 239.3% return, outperforming this stock by 302.9%

Performance

  • $8.13
    $8.78
    $8.43
    downward going graph

    3.56%

    Downside

    Day's Volatility :7.4%

    Upside

    3.99%

    downward going graph
  • $3.21
    $18.33
    $8.43
    downward going graph

    61.92%

    Downside

    52 Weeks Volatility :82.49%

    Upside

    54.01%

    downward going graph

Returns

PeriodIovance Biotherapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-42.09%
-0.3%
0.0%
6 Months
16.05%
7.4%
0.0%
1 Year
-3.51%
11.0%
0.0%
3 Years
-64.26%
17.3%
-24.3%

Highlights

Market Capitalization
2.5B
Book Value
$2.43
Earnings Per Share (EPS)
-1.94
PEG Ratio
0.0
Wall Street Target Price
25.92
Profit Margin
0.0%
Operating Margin TTM
-16464.62%
Return On Assets TTM
-34.48%
Return On Equity TTM
-66.77%
Revenue TTM
1.9M
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-451.0M
Diluted Eps TTM
-1.94
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.37
EPS Estimate Next Year
-0.72
EPS Estimate Current Quarter
-0.42
EPS Estimate Next Quarter
-0.35

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Iovance Biotherapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
18
18
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 207.47%

Current $8.43
Target $25.92

Technicals Summary

Sell

Neutral

Buy

Iovance Biotherapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc.
-21.6%
16.05%
-3.51%
-64.26%
-56.01%
Moderna, Inc.
Moderna, Inc.
17.55%
87.94%
15.42%
-28.78%
814.11%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.19%
17.3%
33.92%
94.36%
234.29%
Novo Nordisk A/s
Novo Nordisk A/s
8.19%
44.85%
81.77%
239.36%
454.2%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.67%
17.46%
39.08%
144.25%
181.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc.
NA
NA
0.0
-1.37
-0.67
-0.34
NA
2.43
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.82
29.82
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.58
49.58
2.36
3.48
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.23
31.23
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc.
Buy
$2.5B
-56.01%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$56.6B
814.11%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.3B
234.29%
29.82
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$636.1B
454.2%
49.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.3B
181.72%
31.23
39.46%

Institutional Holdings

  • Vanguard Group Inc

    8.90%
  • Mhr Fund Management Llc

    8.58%
  • BlackRock Inc

    7.12%
  • Perceptive Advisors LLC

    6.89%
  • venBio Select Advisor LLC

    4.18%
  • State Street Corporation

    3.72%

Corporate Announcements

  • Iovance Biotherapeutics, Inc. Earnings

    Iovance Biotherapeutics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical

Organization
Iovance Biotherapeutics, Inc.
Employees
557
CEO
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Industry
Health Technology

FAQs